HVEM, LIGHT, and BTLA are pivotal in immune modulation, with HVEM emerging as a vital immuno-oncology target. HVEM/LIGHT binding triggers immune activation and apoptosis, offering a dual anti-cancer mechanism. Conversely, HVEM's interaction with BTLA regulates T-cell responses, acting as a molecular switch for immune modulation. These intricate interactions highlight HVEM's potential as a dual-target for cancer therapy and immune regulation.

In response to the advancing needs of drug development, we have developed a broad range of HVEM products. These encompass recombinant HVEM, LIGHT, BTLA, and CD160 proteins, overexpression cell lines for BTLA, HVEM, and LIGHT, as well as reporter cell lines for BTLA and HVEM.

• Recombinant proteins: Available in various species and tags, with high purity and verified binding activity. Active trimer confirmation by SEC-MALS.
• Reporter cell lines: Designed based on explicit mechanism of action, with stable passage over 20 generations.

BTLA Related Product

HVEM Related Product

LIGHT Related produ

Assay Data

• LIGHT: Active trimer structure and high purity (＞90%)verified by SEC-MALS

The purity of Human LIGHT Protein, Fc Tag (Cat. No. LIT-H5269) is more than 90% and the molecular weight of this protein is around 180-200 kDa verified by SEC-MALS.

• BTLA-HVEM Binding Activity Verified by SPR

Loaded Human BTLA (31-150), His Tag (Cat. No. BTA-H52H3) on NTA Biosensor, can Human HVEM, Mouse IgG2a Fc Tag, low endotoxin with an affinity constant of 20.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Awards & Certifications